In breast cancer, dysregulated Hippo signaling results in activation of the YAP/TAZ-TEAD transcriptional complex, which induces a broad oncogenic transcriptional program. This gene expression network promotes tumor cell proliferation, survival, invasion and metastatic dissemination, while also contributing to resistance to anticancer therapies. Researchers from Harbin Medical University reported the preclinical characterization of M-511-0965, a YAP-TEAD4 inhibitor, in models of triple-negative breast cancer (TNBC).